Lantern Pharma Inc.
LTRN
$3.93
$0.133.42%
| Weiss Ratings | LTRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | LTRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | LTRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.11 | |||
| Price History | LTRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 7.38% | |||
| 30-Day Total Return | -15.85% | |||
| 60-Day Total Return | 14.58% | |||
| 90-Day Total Return | 19.82% | |||
| Year to Date Total Return | 19.09% | |||
| 1-Year Total Return | -60.54% | |||
| 2-Year Total Return | -15.48% | |||
| 3-Year Total Return | -43.53% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -67.22% | |||
| 52-Week Low % Change | 40.86% | |||
| Price | LTRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $11.99 | |||
| 52-Week Low Price | $2.79 | |||
| 52-Week Low Price (Date) | Nov 21, 2024 | |||
| 52-Week High Price (Date) | Mar 25, 2024 | |||
| Valuation | LTRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 42.38M | |||
| Enterprise Value | 14.62M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.78 | |||
| Earnings Per Share Growth | 27.41% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 1.59 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $3.93 | |||
| Enterprise Value/EBITDA (TTM) | -0.69 | |||
| Enterprise Value/EBIT | -0.69 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | LTRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 10.76M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | LTRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 972 277 1136 | |||
| Address | 1920 McKinney Avenue Dallas, TX 75201 | |||
| Website | www.lanternpharma.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | LTRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | LTRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -33.94% | |||
| Return on Equity | -- | |||
| Income Statement | LTRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -21.18M | |||
| EBIT (TTM) | -21.20M | |||
| Net Income (TTM) | -19.09M | |||
| Net Income Avl. to Common (TTM) | -19.09M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -42.52% | |||
| EPS Diluted (TTM) | -1.78 | |||
| EPS Diluted Growth (Q YOY) | -43.75% | |||
| Balance Sheet | LTRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 28.05M | |||
| Cash Per Share (Q) | $2.61 | |||
| Total Current Assets (Q) | 29.92M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 26.60M | |||
| Current Ratio (Q) | 8.309 | |||
| Book Value Per Share (Q) | $2.47 | |||
| Total Assets (Q) | 30.29M | |||
| Total Current Liabilities (Q) | 3.60M | |||
| Total Debt (Q) | 291.20K | |||
| Total Liabilities (Q) | 3.70M | |||
| Total Common Equity (Q) | 26.60M | |||
| Cash Flow | LTRN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 178.20K | |||
| Cash from Financing (TTM) | -433.30K | |||
| Net Change in Cash (TTM) | -17.47M | |||
| Levered Free Cash Flow (TTM) | -10.41M | |||
| Cash from Operations (TTM) | -17.23M | |||
